Global logistics provider Kuehne+Nagel has expanded its Cool Corridor network by introducing four new temperature-controlled trade routes, strengthening its ability to transport pharmaceuticals and other sensitive healthcare products across key international markets. The move reflects the company’s continued focus on supporting the growing demand for reliable cold chain logistics amid rising global pharmaceutical trade.
The newly added corridors are designed to maintain strict temperature integrity throughout the transportation process, ensuring compliance with Good Distribution Practice (GDP) standards. By enhancing connectivity between major production and consumption hubs, Kuehne+Nagel aims to provide customers with faster, more secure, and fully monitored transport solutions for high-value, temperature-sensitive cargo.
The Cool Corridor programme integrates validated handling procedures, real-time shipment visibility, risk management protocols, and collaboration with certified airline and airport partners. These measures help minimise temperature excursions and improve supply chain resilience for critical healthcare shipments, including vaccines, biologics, clinical trial materials, and specialty medicines.
The expansion comes as pharmaceutical manufacturers increasingly seek dependable logistics partners capable of handling complex cold chain requirements while meeting stringent regulatory standards. With the addition of the four new routes, Kuehne+Nagel further strengthens its global healthcare logistics network, offering customers broader market access and enhanced service reliability across strategic trade lanes.
The latest development reinforces Kuehne+Nagel’s commitment to investing in specialised healthcare logistics infrastructure and supporting the safe, efficient movement of life sciences products worldwide. The expanded Cool Corridor network is expected to improve supply chain flexibility and help customers navigate evolving global healthcare distribution demands.